Cargando…

Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXRα/PCSK9 pathway

Studies have confirmed that olanzapine, the mainstay treatment for schizophrenia, triggers metabolic diseases, including non-alcoholic fatty liver disease (NAFLD). However, the etiology of olanzapine-induced NAFLD is poorly understood. Proprotein convertase subtilisin kexin type 9 (PCSK9) is involve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Wenqiang, Ding, Chen, Huang, Piaopiao, Ran, Juanli, Lian, Pingan, Tang, Yaxin, Dai, Wen, Huang, Xiansheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979948/ https://www.ncbi.nlm.nih.gov/pubmed/35379885 http://dx.doi.org/10.1038/s41598-022-09610-1

Ejemplares similares

Inhibition of DHCR24 activates LXRα to ameliorate hepatic steatosis and inflammation
por: Zhou, Enchen, et al.
Publicado: (2023)

Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPARγ, LXRα and ABCA1
por: Jia, Qingling, et al.
Publicado: (2019)

Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: a systematic review and meta-analysis
por: Li, Rong, et al.
Publicado: (2020)

Quercetin protects against ox-LDL-induced injury via regulation of ABCAl, LXR-α and PCSK9 in RAW264.7 macrophages
por: Li, Shanshan, et al.
Publicado: (2018)

Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathway
por: Cho, Kumsun, et al.
Publicado: (2015)

Inhibition of LXRα/SREBP-1c-Mediated Hepatic Steatosis by Jiang-Zhi Granule
por: Wang, Miao, et al.
Publicado: (2013)

microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production
por: Dong, Jianjie, et al.
Publicado: (2020)

Metformin ameliorates olanzapine-induced disturbances in POMC neuron number, axonal projection, and hypothalamic leptin resistance
por: Kim, Jaedeok, et al.
Publicado: (2022)

Fisetin ameliorates atherosclerosis by regulating PCSK9 and LOX-1 in apoE(-/-) mice
por: Yan, Li, et al.
Publicado: (2021)

TRPA1 triggers hyperalgesia and inflammation after tooth bleaching
por: Chen, Chang, et al.
Publicado: (2021)

H(2)O(2) gel bleaching induces cytotoxicity and pain conduction in dental pulp stem cells via intracellular reactive oxygen species on enamel/dentin disc
por: Chen, Chang, et al.
Publicado: (2021)

Variations in TM6SF2, PCSK9 and PCSK7 genes and risk of hepatic steatosis after liver transplantation: a cross-sectional study
por: Eshraghian, Ahad, et al.
Publicado: (2021)

Metformin ameliorates olanzapine-induced obesity and glucose intolerance by regulating hypothalamic inflammation and microglial activation in female mice
por: Suh, Sang Bum, et al.
Publicado: (2022)

Metformin ameliorates hepatic steatosis and improves the induction of autophagy in HFD-induced obese mice
por: Li, Min, et al.
Publicado: (2017)

Di-(2-ethylhexyl) Phthalate Limits the Lipid-Lowering Effects of Simvastatin by Promoting Protein Degradation of Low-Density Lipoprotein Receptor: Role of PPARγ-PCSK9 and LXRα-IDOL Signaling Pathways
por: Guo, Bei-Chia, et al.
Publicado: (2023)

Dennd5b-Deficient Mice are Resistant to PCSK9-Induced Hypercholesterolemia and Diet-Induced Hepatic Steatosis
por: Mobilia, Maura, et al.
Publicado: (2022)

LXRα and LXRβ Nuclear Receptors Evolved in the Common Ancestor of Gnathostomes
por: Fonseca, Elza, et al.
Publicado: (2017)

Ouabagenin is a naturally occurring LXR ligand without causing hepatic steatosis as a side effect
por: Tamura, Satoru, et al.
Publicado: (2018)

Metformin Ameliorates Hepatic Steatosis and Inflammation without Altering Adipose Phenotype in Diet-Induced Obesity
por: Woo, Shih-Lung, et al.
Publicado: (2014)

Metformin and Berberine Prevent Olanzapine-Induced Weight Gain in Rats
por: Hu, Yueshan, et al.
Publicado: (2014)

Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?
por: Shek, Aleksandr B., et al.
Publicado: (2019)

Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Wang, Yu, et al.
Publicado: (2016)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia
por: Kratzer, Adelheid, et al.
Publicado: (2009)

Metabolic Modeling Combined With Machine Learning Integrates Longitudinal Data and Identifies the Origin of LXR-Induced Hepatic Steatosis
por: van Riel, Natal A. W., et al.
Publicado: (2021)

Metformin improves nonalcoholic fatty liver disease in obese mice via down-regulation of apolipoprotein A5 as part of the AMPK/LXRα signaling pathway
por: Lin, Min-Jie, et al.
Publicado: (2017)

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
por: Cai, Gaojun, et al.
Publicado: (2018)

A novel dammarane triterpenoid alleviates atherosclerosis by activating the LXRα pathway
por: Huang, Yan, et al.
Publicado: (2023)

Identfication of Potent LXRβ-Selective Agonists without LXRα Activation by In Silico Approaches
por: Chen, Meimei, et al.
Publicado: (2018)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

Gamma-Muricholic Acid Inhibits Nonalcoholic Steatohepatitis: Abolishment of Steatosis-Dependent Peroxidative Impairment by FXR/SHP/LXRα/FASN Signaling
por: Xie, Yang, et al.
Publicado: (2023)

Establishment of a monoclonal antibody for human LXRα: Detection of LXRα protein expression in human macrophages
por: Watanabe, Yuichiro, et al.
Publicado: (2003)

Encapsulation of LXR ligand by D-Nap-GFFY hydrogel enhances anti-tumorigenic actions of LXR and removes LXR-induced lipogenesis
por: Feng, Ke, et al.
Publicado: (2021)

miR-206 controls LXRα expression and promotes LXR-mediated cholesterol efflux in macrophages
por: Vinod, Manjula, et al.
Publicado: (2014)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

Combination of Olanzapine Pamoate with Melatonin and Metformin: Quantitative Changes in Rat Adipose Tissue
por: MIRON, IC, et al.
Publicado: ( 201)

Preventing Olanzapine-Induced Weight Gain Using Betahistine: A Study in a Rat Model with Chronic Olanzapine Treatment
por: Lian, Jiamei, et al.
Publicado: (2014)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_lokr92q43m0if1eqr2qfh0r14r